TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed acute lymphoblastic or biphenotypic leukemia (karyotypic or molecular evidence of Ph)~* Ages of 15-65 years~* Eastern Cooperative Oncology Group performance status of 0-2~* Adequate renal (serum creatinine less than 2 mg/dl, unless considered due to leukemia) and hepatic (serum bilirubin less than 3 mg/dl, unless considered due to leukemia) functions~* Adequate cardiac status (New York Heart Association Class less than or equal to 2)~* Signed informed consent~Exclusion Criteria:~* Pregnant and lactating women will not be eligible. Women of childbearing potential should have a negative pregnancy test prior to entering on the study.~* Active cardiac dysfunction (New York Heart Association Class more than or equal to 3), uncontrolled angina, myocardial infarction (within 6 months), congenital long QT syndrome, any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia or ventricular fibrillation), or prolonged QTc interval on pre-entry electrocardiogram (more than 470 msec)~* Patients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia~* Patients with severe medical conditions that in the view of the investigator prohibits participation in the study~* Treatment with any other investigational antileukemic agents in the last 30 days before study entry

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Modified Hyper-CVAD + Dasatinib (Type: EXPERIMENTAL): Dasatinib: 100 mg once daily, PO, for 4 weeks Cyclophosphamide: 300 mg/m2, IV, every 12 hours, days 1\~3 Vincristine: 1.4 mg/m2/day (maximum 2 mg/day), IV, days 4 \& 11 Daunorubicin: 45 mg/m2/day, IV, days 4 \& 11 Dexamethasone: 40 mg/day, IV, days 1\~4 \& days 11\~14 Cytarabine: 2 g/m2, IV, every 12 hours, days 1\~5 Mitoxantrone: 12 mg/m2/day, IV, days 1\~2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients are aged greater than 20 years who have H. pylori infection without prior eradication therapy and are willing to receive the sequential therapy will be eligible for enrollment.~Exclusion Criteria:~1. children and teenagers aged less than 20 years,~2. history of gastrectomy,~3. gastric malignancy, including adenocarcinoma and lymphoma,~4. previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin, metronidazole) and prompt pump inhibitors (lansoprazole),~5. contraindication to treatment drugs,~6. pregnant or lactating women,~7. severe concurrent disease,~8. Patients who cannot give informed consent by himself or herself.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
- Group B: Sequential therapy for 10 days (Type: EXPERIMENTAL): None
- Group C: Triple therapy for 14 days (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Above 18 years of age~* Have positive SARS-CoV-2 PCR on nasopharyngeal and/or oropharyngeal swabs~* Admitted in isolation ward and ICU of institutes affiliated with DUHS~* have severe or critical COVID 19 as judged by the treating physician~* Consent given by the patient or first degree relative~Exclusion Criteria:~* Pregnancy~* Previous allergic reaction to immunoglobulin treatment~* Ig A deficiency~* Patient requiring 2 inotropic agents to maintain blood pressures~* Known case of any autoimmune disorder~* Acute kidney injury or chronic renal failure~* Known case of thromboembolic disorder~* Aseptic meningitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Standard care only n = 10 patients.
- IVIG dose: 0.15 g/kg (Type: EXPERIMENTAL): Standard Care + Single dose of 0.20 g/Kg anti-COVID-19 IVIG (experimental drug prepared at DUHS) n= 10 patients
- IVIG dose: 0.20 g/kg (Type: EXPERIMENTAL): Standard Care + Single dose of 0.25 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
- IVIG dose: 0.25 g/kg (Type: EXPERIMENTAL): Standard Care + Single dose of 0.30 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients
- IVIG dose: 0.30 g/kg (Type: EXPERIMENTAL): Standard Care + Single dose of 0.35 g/Kg anti-COVID19 IVIG (experimental drug prepared at DUHS) n= 10 patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Increasing Vaccine Uptake Among Adolescents in the Rural South

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~- Any public middle school in Cherokee County, South Carolina or Rockingham County, North Carolina school districts

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- INVEST Intervention School Districts (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent or equivalent document (e.g., written information) as per country regulation prior to registration of any patient data~* Male or female patients aged 18 years or older with a diagnosis of Cushing's disease for whom surgery has failed or for whom surgery is not an option~* Patients must be treated with pasireotide s.c. started either at the first visit for this study or prior to study entry~Exclusion Criteria:~* Patients with ectopic ACTH-dependent Cushing's syndrome~* Patients with adrenal Cushing's syndrome~* Patients with Pseudo Cushing's syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1/new use cohort (Type: None): Subjects who initiated pasireotide s.c. at time of study entry (on or after the signing of the informed consent or acknowledging an equivalent document -for example, written information- as per country regulation).
- Cohort 2/prior use cohort (Type: None): Subjects who initiated pasireotide s.c. prior to study entry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have been diagnosed as Crohn's disease at least 3 months prior to screening.~* Have active Crohn's disease despite adequate conventional therapy.~Exclusion Criteria:~* Patients with severe intestinal strictures (strictures which may affect the number of defecations, etc., or dilation of the colon or strictures in the proximal small bowel observed on barium radiograph, or strictures precluding the insertion of endoscope), a diagnosis of short bowel syndrome, or previous stoma surgery.~* Patients who have a history of treatment with infliximab, or biological products (anti-TNFα agents and anti-IL-6 agents, etc.).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- TA-650 (Type: EXPERIMENTAL): Responder criteria: Case where PCDAI score on the evaluation day was decreased by at least 15 points from that in the screening period and was ≤30.~Criteria for dose-increasing: When either of the following 2 items was satisfied after Week 14, the relevant patient would be considered to satisfy the criteria for dose increasing to 10 mg/kg.~1. PCDAI score on the evaluation day was increased by at least 15 points compared to the lowest PCDAI score observed at Week 2, 6 or 10~2. PCDAI score on the evaluation day exceeds 30

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be willing and able to sign consent forms;~* Be eligible for menstrual regulation (MR) services according to clinician's assessment;~* Be willing to undergo a surgical evacuation if necessary;~* Be willing to provide a urine sample prior to administration of the mifepristone~* Have ready and easy access to a telephone and~* Agree to comply with the study procedures and visit schedule~Exclusion Criteria:~* • Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;~  * Chronic renal failure;~ * Concurrent long-term corticosteroid therapy;~ * History of allergy to mifepristone, misoprostol or other prostaglandin;~ * Hemorrhagic disorders or concurrent anticoagulant therapy;~ * Inherited porphyrias; or~ * Other serious physical or mental health conditions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mifepristone-misoprostol (Type: EXPERIMENTAL): Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Must not be pregnant or breastfeeding and agree to use birth control;~* Completion of a negative colonoscopy as per American Gastroenterology Association (AGA) criteria and no clinically-significant laboratory or physical examination findings;~* Meets protocol-defined criteria for IBS-C, including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria;~* Demonstrates English fluency and has access to a touch-tone telephone.~Exclusion Criteria:~* Recent history of mushy or watery stools;~* Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study;~* Clinically-significant alarm symptoms;~* Secondary causes of constipation or evacuation disorders;~* Surgery to the gastrointestinal tract;~* Usage of prohibited medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 72 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 145 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 290 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- 579 ug linaclotide acetate (Type: ACTIVE_COMPARATOR): None
- Matching Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 18-80 years of age with active RA;~* patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit;~* eligible for re-treatment, based on clinical symptoms;~* patients of reproductive potential must be using reliable contraceptive methods.~Exclusion Criteria:~* patients who participated in MabThera study WA17042 but withdrew into the safety follow-up;~* current treatment with any other disease-modifying antirheumatic drug (apart from methotrexate), or any anti-TNFalfa, anti-IL1, or other biologic therapies;~* development of any new contraindications to receiving MabThera;~* women who are pregnant or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MabThera/Rituxan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit~* Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening visit.~Exclusion criteria:~* Screening HbA1c \< 7.0% and \> 10.0%~* Fasting plasma glucose at screening \> 250 mg/dL (\> 13.9 mmol/L)~* Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening, previous use of insulin~* Participants who usually did not eat breakfast~* Type 1 diabetes mellitus~* Body Mass Index (BMI) ≤ 20 kg/m\^2 and \> 40 kg/m\^2~* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method~* Amylase and/or lipase \> 3 times the upper limit of the normal laboratory range ( ULN) at screening~* Alanine aminotransferase (ALT) \> 3 ULN at screening~* Calcitonin ≧ 20 pg/ml (5.9 pmol/L) at screening~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes)~* Any contra-indication related to metformin~* Any previous treatment with lixisenatide~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lixisenatide Main Meal (Type: EXPERIMENTAL): Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24.
- Lixisenatide Breakfast (Type: ACTIVE_COMPARATOR): Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-surgical Intervention for Carpal Tunnel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults \> 18 years of age~* Fluent in English~* Report signs and symptoms of carpal tunnel syndrome~* Pain, numbness, and tingling of the forearm, wrist, or hand, which worsen at night~* Demonstrate positive Phalen's Test or Tinel's Test of the affected extremity~Exclusion Criteria:~* Currently receiving treatment for carpal tunnel syndrome~* History of surgical carpal tunnel release~* Pregnant~* Diabetes not controlled by medication~* Radiculopathy ie: cervical radiculopathy, diabetic radiculopathy~* Thoracic outlet syndrome~* Allergy to adhesives or compromised skin integrity~* Past history of traumatic event, surgery, or congenital impairment of the forearm, wrist, or hand

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Kinesio Tape (Type: EXPERIMENTAL): Dorsal application of Kinesio Tape to the affected extremity: Approximately 12 inches of Kinesio tape will be applied from the musculotendinous junction of the participant's forearm over digits 1 and 5. Two - 2 inch strips of Kinesio Tape will be applied to the participant's wrists over the volar and dorsal aspects. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application by the researchers four times during the course of the study.~A tape removal form will be provided should the participants want to remove it prior to the next visit.
- Control group (Type: SHAM_COMPARATOR): Approximately 4 inch strip of Kinesio Tape will be applied to the scapular spine of the same side as the affected extremity. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application four times during the course of the study by the researcher. A tape removal form will be provided should the participants want to remove it prior to the next visit.
- Standard of Care (Type: ACTIVE_COMPARATOR): Currently, the standard of care is a general cock-up splint and lumbrical exercises. A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA~* Males and Females ≥ 18 years old diagnosed with HER2 positive breast cancer~* Scheduled to receive neoadjuvant or adjuvant trastuzumab (Herceptin®) therapy (anthracycline-containing regimens are permitted). Patients receiving Herceptin® with their chemotherapy are permitted for eligibility work-up. Taxanes are permitted. Trastuzumab (Herceptin®) therapy may be given with or after primary chemotherapy. Pertuzumab may be used in conjunction with trastuzumab.~* Left Ventricular Ejection Fraction (LVEF) ≥ 50% by MUGA scan or echocardiogram~* Adequate renal function for administration of trastuzumab-containing chemotherapy regimen.~* Sitting systolic blood pressure of \> 90 mm Hg~* Pulse ≥ 60 beats/minute~* Not pregnant or breastfeeding~* Female patients of childbearing potential, who are sexually active, must have a negative pregnancy test before starting the study~* Both men and women must be willing to use effective contraception during the study. Teratogenicity is documented for both active study agents~* Able to swallow capsules~EXCLUSION CRITERIA:~* Patients with metastatic disease~* Prior treatment with trastuzumab or anthracyclines prior to this chemotherapy regimen~* Current treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), such as losartan, β-blockers or digoxin~* Known cardiac history: heart failure, myocardial infarction, radiation-induced cardiac dysfunction~* Known allergy to either ACE inhibitors or β-blockers~* History of bronchial asthma or related bronchospastic conditions~* Hereditary or idiopathic angioedema~* History of severe hypersensitivity reactions to drugs or other causes, i.e. bee stings~* This protocol does not exclude patients who are participating on other investigational studies. Refer to the local IRB guidelines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I lisinopril (Type: EXPERIMENTAL): Patients receive oral lisinopril once daily.
- Arm II Coreg CR® (Type: EXPERIMENTAL): Patients receive oral Coreg CR® once daily.
- Arm III placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete